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Historical background
Pleuropulmonary and retroperitoneal fibrotic reactions have been described with the use of the ergot-derived drugs methysergide and ergotamine since 1966. [1] [2] [3] [4] Afterwards, several additional case reports were published about cardiac pericardial and valvular fibrotic side effects of these drugs. [5] [6] [7] In 1997, fenfluramine and phentermine (Fen-Phen), both appetite suppressants, were withdrawn after the report of important valvular heart disease (VHD) in young women. 8 Subsequent retrospective echocardiographic studies confirmed the relation between (dex)fenfluramine and VHD. [9] [10] [11] [12] [13] Later on, other ergot-derived drugs as pergolide and cabergoline were also suspected of inducing valvular regurgitations. [14] [15] [16] [17] [18] [19] This has led to the spontaneous withdrawal of pergolide by manufactures of the US market in 2007. The association between certain drugs and valvular lesions identified a 'new' cause of VHD which can be called 'drug-induced VHD' or 'toxic heart valvulopathy'.
Echocardiography and toxic valvulopathies: is this real?
The Fen-Phen story has led to a controversy in medical literature about the real incidence of fenfluramine-induced valvulopathy. 20 The main reason for this was that Fen-Phen was withdrawn after a few case reports (five confirmed histopathologically) demonstrating analogue changes as in carcinoid syndrome, while it had already been prescribed in nearly 5 million US adults. 8, 9 Subsequent uncontrolled echocardiographic surveys showed initially high risks of fenfluramine-induced VHD [18% with light to moderate aortic regurgitation (AR) and 5% moderate to severe mitral regurgitation (MR); these were the criteria the FDA proposed for the diagnosis of toxic valvulopathy]. 21 However, subsequent controlled studies showed a clearly reduced, but still present risk for AR (9.7%) and MR (2.9%). 21 This shows that several methodological issues initially overestimated the incidence of fenfluramine and VHD. 21 It is interesting to note that the incidence of echocardiographically detected toxic valvulopathy was highest in the USA when pharmaceutical companies had to reimburse several damage claims. This underlines the importance of blinding during echocardiographic acquisition and interpretation. Also, study patients did not routinely have echocardiography prior to drug therapy and it is, therefore, unclear how many may have had pre-existent valvular abnormalities. Moreover, the prevalence of regurgitant valvular lesions in obese patients not exposed to these drugs is not wellestablished. 13, 22, 23 Although discussion can persist about the real incidence of drug-induced VHD, all the clinical data available together with the reproducibility of drug-induced VHD in prospective small animal studies proves that toxic valvulopathy really exists ( Figure 1A and B).
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Morphological and echocardiographic characteristics Histopathological features
Drug-induced VHD shows clinical, histopathological, and pathophysiological similarities with the carcinoid syndrome. 25, 26 The latter occurs in only 10% of patients with carcinoid tumours when hormonally vasoactive tumour products exceeding the hepatic capacity for degradation (in case of hepatic metastasis) reach the systemic venous circulation. Serotonin is a key element hereby that induces right-sided VHD in 40% of patients. [27] [28] [29] The presence of left heart disease is less frequent as serotonin is normally degraded by monoamine oxidase in the lungs (except in pulmonary metastasis or patent foramen ovale). 25, 30 In contrast, drug-induced VHD affects even more importantly the aortic and mitral valves. 31 The serotonin 2B (5HT 2B ) receptor has been postulated as the main pathway through which these drugs and serotonin induce VHD. 26, [32] [33] [34] [35] [36] [37] [38] [39] Overstimulation of this receptor leads to valvular fibroblast proliferation and activation with the production of collagen and glycosaminoglycans. This leads to superficial plaque-like thickening of the valvular leaflets and subvalvular apparatus composed of fibromyxoid tissue. Usually, no signs of calcification are present. Macroscopically, valves and tendinous cords are thickened, shortened, and may have a pearly white appearance (Figure 2A and B) . 8, 16 However, valvular lesions associated with anorexigens have been shown to have some different microscopic features whereby more glycosaminoglycan deposition and fewer vessels are found compared with carcinoid heart disease. 40 This suggests that a more specific and distinctive myxomatous process may be present in anorexigen-exposed valves. Yet, it is not clear if this is also the case for the ergot derivates.
Echocardiographical characteristics
Echocardiography is the key examination for the diagnosis of toxic valvulopathy. Typically, this is characterized by thickening of the valvular leaflets and thickening and shortening of the subvalvular apparatus of the mitral ( Figure 3A and B) and tricuspid valve. In this way, the leaflets are more retracted towards the apex and their mobility is reduced during systole (tenting) with regurgitation as a consequence. For the aortic valve, this leads to systolic doming of the thickened leaflets with reduced mobility and incomplete coaptation during diastole and consequent regurgitation ( Figure 4A-D) . 16 In younger patients (,50 years), the background prevalence of AR and MR in normal subjects is low or even absent. 41 Therefore, the FDA criteria mentioned above could be applied for the diagnosis of toxic valvulopathy. However, in older patients, i.e. with Parkinson's disease, underlying valvular sclerosis and calcification might be present with AR or MR. For this reason, the FDA criteria cannot be simply used in this subgroup of patients. Consequently, some authors used a scoring system from 1 to 4 (from very likely to unlikely) whereby restrictive tricuspid valve motion was given more power for defining ergot-like abnormalities compared with mitral and aortic restrictive function: 1, proven restrictive VHD (confirmed with histopathology, regression after interruption of ergot treatment, or both); 2, important valvular disease (regurgitant jet !2/4) suggestive of restrictive VHD or restrictive tricuspid disease even if ,2/4; 3, mild to moderate (regurgitant jet ,2/4) restrictive valvular disease; and 4, no restrictive valvular dysfunction. 16 Another method to describe the restrictive pattern of the tricuspid or mitral valve is to measure the tenting area and distance as described in ischaemic heart disease. However, this might be more subjective and less reproducible in this setting. Before the diagnosis of drug-induced VHD can be made, also other causes of restrictive VHD need to be excluded: remodelling of the left ventricle (i.e. ischaemic MR), rheumatic heart and other interstitial diseases, carcinoid syndrome, cardiac mass, infectious endocarditis (i.e. intravenous drug use), and congenital abnormalities. In rheumatic heart disease, valvular damage and thickening is usually more pronounced and to a certain extent commissural fusion of valvular leaflets occurs leading to valvular stenosis, which is not a typical feature of drug-induced VHD. As usual, blood pressure should be a part of the echocardiographic examination since it might influence the severity of MR and AR.
Drugs associated with valvular heart disease
For overview see Table 1 .
Ergotamine and methysergide
Ergotamine and methysergide were the first drugs described to be associated with VHD since 1966. 1 Until the early 1990s, only sporadic cases were reported. [43] [44] [45] With the routine use of two-dimensional echocardiography and later on second harmonic imaging, valvular morphology and function were easier to evaluate. This led to a better echocardiographic and pathological correlation and an increased awareness and reports of toxic valvulopathy. 46 Ergotamine and methysergide are still used in some countries for the prophylactic treatment of vascular headache and before 1990 toxic valvulopathy remained mostly undiscovered until symptoms occurred such as fatigue, dyspnoea, chest pain, palpitations, and a new heart murmer. 7 At that point, valvular damage was already pronounced so that valvular replacement seemed the only therapeutical option. There are no 64 CR, case report; R-CT, retrospective case-control trial; CS-CT, cross-sectional case-control trial; M, meta-analysis; in vitro evidence; in vivo evidence; AV, aortic valve; MV, mitral valve; TV, tricuspid valve; OR, odds ratio. All clinical studies are observational and not randomized.
reports of case-control series of ergotamine or methysergide-induced VHD and no dose-dependent relation has ever been described.
Fenfluramine/phentermine and dexfenfluramine
In 1997, Connolly et al. 8 reported a series of case reports of young women that developed VHD several months after treatment with the anorectic agents (dex)fenfluramine and the combination Fen-Phen. Echocardiographically and histopathologically, these valves showed a striking resemblance to carcinoid syndrome and above-mentioned drugs. Based on this study and other case reports, the FDA reported that toxic valvulopathy was identified in 113 young women (mean age 44 year) that took slimming drugs and valvular replacement was needed in 24% of patients. These findings led to the rapid withdrawal of fenfluramine from the market in 1997. 9 Later on, several retrospective casecontrol and follow-up studies have been published confirming the association between (dex)fenfluramine use and VHD. 13, 22, 23, [47] [48] [49] A subsequent meta-analysis conducted by Sachdev et al. 10 in 2002 showed that (dex)fenfluramineinduced VHD was less common than initially reported, but still present in one out of eight patients treated for more than 90 days. In another meta-analysis by Hopkins and Polukoff, 11 a much higher relative risk for aortic (RR 19,6) and mitral (RR 5,9) valvulopathy after (dex)fenfluramine exposure was found compared with previous reports when they corrected for several bias factors. The same group recently published the largest single centre observational study in 5743 patients that had taken fenfluramine before. In this study, the prevalence of FDA-positive AR or MR was 19.6% in women and 11.8% in men. 50 Valve surgery was performed on 38 patients (0.66%), 25 (0.44%) with clear evidence of fenfluramine-related aetiology.
Pergolide and cabergoline
In 2002, Pritchett et al.
14 reported the association between pergolide and VHD for the first time. This relation was confirmed in 2004 by Van Camp et al. 16 in a cross-sectional case-control study of 78 patients with Parkinson's disease treated with high dose pergolide. Restrictive VHD with MR, AR, and tricuspid regurgitation was found in 33% of patients treated with pergolide. Besides increased prevalence of valvular regurgitation, also an increase in mitral tenting areas and distances were found in the pergolide group compared with controls. Pergolide and also cabergoline are ergot-derived dopamine agonists with an ergolinic structure and 5-HT 2B agonist activity. Recent population-based studies have more clearly defined the relative risk associated with the use of different agonists in patients with Parkinson's disease. From these studies, a clearly increased risk for the development of toxic valvulopathy with pergolide and cabergoline use [16] [17] [18] [51] [52] [53] [54] was found. A recent review by Antonini and Poewe 42 calculated from these studies a prevalence of 22 and 34% of moderate to severe regurgitation in at least one heart valve in patients with Parkinson's disease treated with pergolide and cabergoline, respectively. All these studies were conducted in patients from Europe or North America. Similar to these studies, a Japanese study of Yamamoto et al. 53 reported an increased risk of valvular regurgitation in patients taking cabergoline. However, this Japanese and a Korean study were excluded from this analysis because average daily pergolide dose was 1.40 and 1.13 mg, respectively, compared with 3.0 mg in the other studies. 53, 55 The low dose of pergolide used in Asian patients could explain why no increased rates of regurgitation were found. A recent meta-analysis and observational study by Corvol et al. 56 found a similar prevalence of 22% of moderate to severe valvulopathy in pergolidetreated patients compared with 7.1% in the control group. In another meta-analysis by Simonis et al., 57 including seven cross-sectional studies with 477 patients treated with ergot-derived dopamine agonists pergolide or cabergoline, a prevalence of 26% of moderate to severe VHD was found compared with 10% in non-ergot-derived dopamine agonists and 10% in controls.
Cabergoline is also used for the treatment of prolactinoma. In contrast to Parkinson's disease, this population is younger with a more female predominance and most importantly, the cumulative dose is about 10 times less. Until now, seven cross-sectional studies have been published of which six did not find an association with clinically relevant regurgitation as reported by Kars et al. 58 However, one study shows a significant increase in moderate tricuspid regurgitation, and two studies show a mild increase in tricuspid regurgitation. [59] [60] [61] The clinical relevance of these findings is therefore still uncertain.
Bromocriptine
One recent cross-sectional case-control study from Singapore found an increased risk of valvular regurgitation in Parkinson's patients treated with bromocriptine compared with controls. 62 However, another study in Korea did not find increased frequencies of valvular regurgitation in patients treated with bromcriptine. 55 This might be due to a lower cumulative dose in the latter study. Bromocriptine is a weak partial 5-HT 2B receptor agonist and was not thought to be associated with toxic valvulopathy. More studies are needed to confirm this possible relation between bromocriptine and toxic valvulopathy.
3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy')
Besides above-mentioned drugs, also 3,4-methylenedioxymethamphetamine (MDMA) is a potent 5-HT 2B receptor agonist and induces fenfluramine like proliferations of human valvular interstitial cells in vitro. 63 Until now, only one cross-sectional case-control study has been published, suggesting an association between MDMA abuse and toxic valvuopathy. 64 An increased incidence of AR and MR was found in patients younger than 30 years old taking MDMA on a regular and recreational basis compared with ageand sex-matched controls. MDMA is not only used for recreational purposes, but is currently under investigation for the treatment of post-traumatic stress syndrome. By consequence, these findings may have important health implications, but need to be confirmed by larger trials.
Other drugs
Two case reports suggest an association between benfluorex, an amfetamine derivative also used as an anorexigen, and toxic valvulopathy. 65, 66 Here too, more studies are needed to investigate this relation.
In light of above-mentioned studies, concerns were also raised about the possibility of an association between selective serotonin-reuptake inhibitors (SSRIs) and toxic valvulopathy because SSRIs also increases local concentrations of serotonin. In an echocardiographic retrospective study conducted by Mast et al., 67 they could not find any difference in VHD between 292 SSRI and 5145 control patients. No other study has addressed this issue. It might be that serotonin increase by SSRIs is not high enough to induce VHD. 68 Furthermore, SSRIs have no 5-HT 2B agonistic properties compared with the fenfluramine derivatives. 26 Until now, no toxic valvulopathy has been described with lisuride (also an ergolinic ergot-derived dopamine agonist) and non-ergot-derived dopamine agonists (such as pramipexole and ropinirole). This indirectly confirms the 5-HT 2B receptor hypothesis as these drugs are devoid of such activity. 69 
Influence of drug dose, treatment duration, and risk factors
Besides the aetiological association, some studies also addressed the issue of dose dependency and other risk factors that could influence the progression towards toxic valvulopathy. This has mostly been studied for the anorectic agents, pergolide, and cabergoline. Based on the data of these studies, such dose-dependent relation is very likely to exist.
In 1999, Li et al. 70 examined 74 case reports received by the FDA, meeting FDA case definition for valvulopathy. They found that patients with severe aortic or mitral VHD were more likely to have taken more than 60 mg fenfluramine a day. In another study, Jollis et al. 71 performed an echocardiogram in 1163 patients that had taken fen-phen compared with 672 controls. An increased risk of aortic valvulopathy was observed according to fen-phen treatment duration. The relative risk for aortic valvulopathy increased from 2.4 at 6 months of fen-phen treatment to 6.2 at 2 years. This was not found for the mitral valve. A smaller uncontrolled observational study (85 patients) of Lepor et al. 72 also suggested an increased risk of combined aortic and mitral valvulopathy with fen-phen daily treatment dose (.60 mg) and duration. In Hopkins' meta-analysis, appearance of new AR was strongly related to the duration of (dex)fenfluramine exposure, while this was not found for the mitral valve. In their recent observational study (Dahl et al. 50 ) of 5743 patients, duration of fenfluramine use was strongly predictive for AR, MR, and TR.
For pergolide and cabergoline, convincing data about such dose-dependent relationship also exist. As already mentioned above, studies that investigated relatively high dosages of pergolide (.3-5 mg/day) found an increased risk of toxic aortic, mitral, and tricuspid valvulopathy, while this was not the case for studies reporting lower dosages. 16, 55, [73] [74] [75] This was also found in two recent studies, whereby high daily dosages or higher cumulative dose of pergolide and cabergoline increased the risk of valvulopathy. 17, 18 In a recent meta-analysis by Corvol et al., 56 the risk of developing valvulopathy was significantly correlated with pergolide cumulative dose. For cabergoline-induced valvulopathy, also an association was found with daily dose, cumulative dose, and treatment duration. 53, 75 In contrast to the anorexigens, no separate data of the aortic or mitral valve with regard to dose relationship have been reported for the dopamine agonists pergolide and cabergoline.
Besides daily drug dose and duration exposure, other factors may influence the evolution towards toxic valvulopathy. Some case reports describe the development of severe valvulopathy even at low dosages of pergolide. [76] [77] [78] Moreover, two-third of patients does not develop valvulopathy, despite several years' exposure, suggesting that susceptibility is a key factor. Subgroups of patients may be at a higher risk of VHD. One cross-sectional study in 412 patients exposed to dexfenfluramine found that factors independently related to FDA defined aortic valvulopathy were older age, higher diastolic blood pressure at the time of echocardiography, and shorter time from drug discontinuation to echocardiogram. 79 In the study of Dahl et al., 50 age and fenfluramine use in women were higher risk factors. For the dopamine agonists age, Parkinson's disease duration and sex seem not related to an increased risk of toxic valvulopathy. 53, 56 However, these factors were secondary end-points in these studies. In a recent case-control study by Oeda et al. 80 conducted in 223 patients with Parkinson's disease receiving pergolide or cabergoline, age above 70 years and hypertension manifestly increased the risk of valvular regurgitation (relative risk 94). These data suggest that special attention should be paid when prescribing pergolide or cabergoline in older hypertensive patients.
Natural course of toxic valvulopathy: does reversibility exist?
Echocardiographic follow-up studies of patients with toxic valvulopathy show that regression of VHD may occur in some patients.
Hensrud et al. 81 described in 1999 the regression of VHD after 6 months in 8 of 15 subjects who had discontinued Fen-Phen, while no worsening was found. Similar findings were observed in a larger study of 50 patients with previous exposure to fenfluramines. 82 In serial echocardiograms obtained 12 months apart, MR and AR improved at least by one grade in 45 and 44% of patients, respectively. Nonsignificant progression of AR and MR was found in 4%. In a large double-blind placebo-controlled trial, 914 patients were followed 1 year after dexfenfluramine exposure of 3 months. 83 Compared with the placebo group, a greater proportion of patients previously treated with dexfenfluramine had a decrease in AR of at least one grade (5.8% of patients). There were no significant changes in MR or leaflet mobility and no progression of valvular regurgitation was found. In another large trial by Gardin et al., 84 1142 obese patients with longer anorexigen exposure (range from 1 to 63 months) were followed for 1 year. Significant echocardiographic regression of AR was noted in 6.4% of dexfenfluramine patients and 4.5% of fen-phen patients compared with 1.7% of controls. In this study, neither significant progression of VHD (0.2%) nor changes in mitral valve regurgitation or leaflet mobility and thickness were found. In the study by Dahl et al., 50 follow-up echocardiograms were available in 1020 fenfluramine users. With a mean follow-up time of 30 months, most regurgitations remained unchanged while improvement was found in one quarter and worsening in 17% of patients. Only in this study progression occurred in some patients, while this was unlikely in the other follow-up studies. Most importantly, regression might occur in up to one-third of patients, even soon after 6 months. However, in patients with end-stage renal disease due to Chinese herbs, a high incidence of fenfluramine-induced AR (52%) has been observed even 6 years after stopping appetite suppressants. 85 In this case, the potential role for reversibility could have been altered because of long treatment with high dose of appetitesuppressants in these patients taken together with the metabolic disturbances due to renal failure. It is not clear from these studies if more damaged valves are less likely to regress.
For pergolide, only few follow-up data are available. When combining several case reports, regression of VHD has only been described in 12 out of 24 patients about who a follow-up has been reported. 16, 19, 86, 87 Only one recent case-control study describes the echocardiographic follow-up in 10 patients in whom pergolide was recently stopped because of restrictive VHD. 88 After 13 months, a significant improvement was found in six patients for MR, but not for AR. In two patients who refused to stop pergolide, valvulopathy remained unchanged. However, this was a very small study and no follow-up data were reported on restrictive mobility.
Regarding causal relationship, cumulative dose and potential for reversibility of drug-induced VHD, only indirect clinical data exist since prospective randomized trials are difficult to conduct, because of evident ethical considerations. Echocardiography in small animals may overcome these limitations because recent reports show the feasibility of studying drug-induced VHD in rats. 24, 27, 34, 89 Such model also has the potential to screen new candidate drugs for toxic valvular side effects and to evaluate new treatment strategies involving the 5-HT 2B receptor.
Practical recommendations for the use of potential valvulopathic drugs
The awareness of potential valvulopathy risk with pergolide among European neurologists has already led to more prudent use and more careful clinical and echocardiographical follow-up. 90 Echocardiography is the method of choice for evaluating valvular morphology and function before, during, and after treatment of potential valvulopathic drugs. It allows reliable and reproducible quantification of valvular function and also valvular motion in terms of valve tenting area and distance. However, subtle and early changes in valvular function and motion (regurgitation and thickening) are more difficult to evaluate and subject to the echocardiographers' experience and interpretation.
Toxic valvular side effects in young patients taking slimming drugs for esthetical considerations or amphetamines for recreational purposes are unacceptable. Therefore, studies investigating MDMA for, for instance, post-traumatic stress syndrome or other amphetamine-like products with possible 5-HT2B activity, such as methylphenidate (Rilatinew) in attention deficit hyperactivity disorder, 91 should include careful echocardiographic valvular follow-up. This is not the case at this moment (see registered study protocols at www.clinicaltrials.gov). Moreover, it is not known yet what the long-term consequences are when valvular damage occurs at a young age. On the other hand, this reasoning cannot be extrapolated to older patients such as in Parkinson's disease in whom quality of life depends on the control of their symptoms. In this population, the riskbenefit ratio of a potential toxic treatment has to be taken into account. Only if insufficient motor control is achieved with classical dopamine-agonists, pergolide or cabergoline may be considered. Patients should be informed about the potential risk and carefully evaluated before and during their treatment with echocardiography. In this way, new or worsening of pre-existing VHD is easier to diagnose. Since the risk for VHD increases with age, blood pressure, drug dose and duration, and other yet unidentified factors, the lowest possible dose for symptom control should be aimed at. If nevertheless toxic valvulopathy develops, cessation of the treatment might lead to regression of valvular regurgitation.
At this moment, no guidelines have been issued by the ESC or ACC/AHA regarding the cardiac management and attitude towards the use of 'valvulopathic' drugs. This is mainly due to the limited and observational nature of studies available.
Future (pre)clinical studies might identify in greater detail which patients are at the risk of developing toxic valvulopathy. Also the exact pathophysiological mechanism(s) need to be further elucidated in order to predict the valvulopathic risk of certain drugs. This might also give the opportunity to develop specific prophylactic or therapeutic strategies.
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